Skip to main content

Table 1 Baseline characteristics and pre-operative variables

From: Initial experience with a synthetic sealant PleuraSeal™ after pulmonary resections: a prospective study with retrospective case matched controls

Variablea Overall PleuraSeal™ Group Control Group p-valueb
  40 20 20  
Age (yrs.), mean (SD) 69 (45-82) 66 (47-81) 0.34
Gender
Male 31 (77%) 14 (70%) 17 (85%)  
Female 9 (22%) 6 (30%) 3 (15%) 0.45
Chronic lung disease 22 11 11  
COPD 19 (47%) 9 (45%) 10 (50%)  
Lung emphysema 2 (5%) 2 (10%) 0 (0%)  
Asthma 1 (2%) 0 (0%) 1 (5%) 0.58
Pulmonary function c
FEV1 actual (Ø %), mean (SD) 85.5 (17.9) 87 (20.2) 84 (15.6) 0.51
FEV1 predicted (Ø %), mean (SD) 65.5 (16.2) 69 (17.6) 62 (14.8) 0.18
DLCO actual (Ø %), mean (SD) 70.5 (14.5) 70 (15.7) 71 (13.3) 0.84
DLCO predicted (Ø %), mean (SD) 55 (14.6) 56 (16.3) 54 (12.9) 0.55
Neoadjuvant therapy 1 0 1  
Radiation 0 (0%) - - NA
Chemotherapy 1 (2%) 0 (0%) 1 (5%) 1.00
Concomitant disease 23 14 9  
Diabetes 7 (17%) 4 (20%) 3 (15%) 1.00
Othersd 16 (40%) 10 (50%) 6 (30%) 0.23
Smoking behaviour
Current Smoker 15 (37%) 8 (40%) 7 (35%)  
Ex smoker (≥12 month) 13 (32%) 6 (30%) 7 (35%)  
Never smoked 12 (30%) 6 (30%) 6 (30%) 0.14
  1. aNumbers in percentage were rounded up were indicated.
  2. bContinuous variables were compared between groups by Students' t-test. Categorical variables were compared using two-sided Fisher's Exact test..
  3. cPreoperative pulmonary function test and postoperative variables based on amount of lung resection; FEV1: Forced expiratory volume (1 sec); DLCO: CO volume-adjusted diffusion capacity). Data shown in % of total function and as mean with SD where indicated; SD standard deviation.
  4. dOther entities: hypertension, cardiac insufficiency, arrhythmia absoluta